stockrow
Saturday 7 November 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
0.85
0.00
0.00%
Follow MLEC
Alert me
Moolec Science SA (MLEC) P/E ratio
Moolec Science SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 409× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 409×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| MLEC Moolec Science SA | n/m |
| JAGX Jaguar Animal Health, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)